Patient Name UHID Age/Gender IP/OP Location Referred By Mobile No.	Mr. HARI MOHAN MEENA 40012947 35 Yrs/Male O-OPD Dr. EHS CONSULTANT 9610450468			Lab No Collection Date Receiving Date Report Date Report Status	4030810 13/04/2024 10:00 13/04/2024 10:08 13/04/2024 5:36 Final	BAM
			BIOCHEMIST	RY		
Test Name		Result	Unit	Biolog	gical Ref. Range	
BLOOD GLUCOSE (F	ASTING)					Sample: Fl. Plasma
BLOOD GLUCOSE (F	ASTING)	104	mg/dl	71 - 109		
Method: Hexokinas Interpretation:-D various diseases.	e assay. iagnosis and monitoring of	treatment in d	liabetes mellitu	s and evaluation of o	carbohydrate metaboli	.sm in
BLOOD GLUCOSE (P	<u>Р)</u>					Sample: PLASMA
BLOOD GLUCOSE (P	Р)	103	mg/dl		etic: - < 140 mg/dl tic: - 140-199 mg/dl =200 mg/dl	
Method: Hexokinas Interpretation:-D various diseases.	e assay. iagnosis and monitoring of	treatment in d	diabetes mellitu	s and evaluation of o	carbohydrate metaboli	sm in

THYROID T3 T4 TSH				Sample: Serum
ТЗ	1.520	ng/mL	0.970 - 1.690	
Τ4	6.61	ug/dl	5.53 - 11.00	
TSH	5.42 H	μIU/mL	0.40 - 4.05	

RESULT ENTERED BY : NEETU SHARMA

AldrinayVerna

Dr. ABHINAY VERMA

Patient Name	Mr. HARI MOHAN MEENA	Lab No	4
UHID	40012947	Collection Date	1
Age/Gender	35 Yrs/Male	Receiving Date	1
IP/OP Location	O-OPD	Report Date	1
Referred By	Dr. EHS CONSULTANT	Report Status	F
Mobile No.	9610450468		

BIOCHEMISTRY

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T3 is utilized in the diagnosis of T3-hyperthyroidism the detection of early stages of hyperthyroidism and for indicating a diagnosis of thyrotoxicosis factitia.

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs acompetitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA

Interpretation:-The determination of TSH serves as theinitial test in thyroid diagnostics. Even very slight changes in theconcentrations of the free thyroid hormones bring about much greater oppositechanges in the TSH levels.

LFT (LIVER FUNCTION TEST)

BILIRUBIN TOTAL	0.46	mg/dl	0.00 - 1.20
BILIRUBIN INDIRECT	0.29	mg/dl	0.20 - 1.00
BILIRUBIN DIRECT	0.17	mg/dl	0.00 - 0.30
SGOT	31.0	U/L	0.0 - 40.0
SGPT	60.8 H	U/L	0.0 - 41.0
TOTAL PROTEIN	7.6	g/dl	6.6 - 8.7
ALBUMIN	4.7	g/dl	3.5 - 5.2
GLOBULIN	2.9		1.8 - 3.6
ALKALINE PHOSPHATASE	117	U/L	40 - 129
A/G RATIO	1.6	Ratio	1.5 - 2.5
GGTP	45.0	U/L	10.0 - 60.0

RESULT ENTERED BY : NEETU SHARMA

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Sample: Serum

4030810 13/04/2024 10:00AM 13/04/2024 10:08AM 13/04/2024 5:36PM Final

Patient Name	Mr. HARI MOHAN MEENA	Lab No	4030810
UHID	40012947	Collection Date	13/04/2024 10:00AM
Age/Gender	35 Yrs/Male	Receiving Date	13/04/2024 10:08AM
IP/OP Location	O-OPD	Report Date	13/04/2024 5:36PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9610450468		

BIOCHEMISTRY

BILIRUBIN TOTAL :- Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structive.

BILIRUBIN DIRECT :- Method: Diazo method Interpretation:-Determinations of direct bilirubin measure mainly conjugated, water soluble bilirubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT(AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

SGPT - ALT :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT(ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS :- Method: Biuret colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder. ALBUMIN :- Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis, nutritional status. ALKALINE PHOSPHATASE :- Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in

ALKALINE PHOSPHATASE :- Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. GGTP-GAMMA GLUTAMYL TRANSPEPTIDASE :- Method: Enzymetic colorimetric assay. Interpretation:-y-glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

LIPID PROFILE

TOTAL CHOLESTEROL	180		<200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High
HDL CHOLESTEROL	37.1		High Risk :-<40 mg/dl (Male), <40 mg/dl (Female) Low Risk :->=60 mg/dl (Male), >=60 mg/dl (Female)
LDL CHOLESTEROL	125.6		Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl
CHOLESTERO VLDL	42	mg/dl	10 - 50
TRIGLYCERIDES	212		Normal :- <150 mg/dl Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl
CHOLESTEROL/HDL RATIO	5	%	

RESULT ENTERED BY : NEETU SHARMA

Alerinary Van

Dr. ABHINAY VERMA

Patient Name UHID	Mr. HARI MOHAN MEENA 40012947	Lab No Collection Date	4030810 13/04/2024 10:00AM
Age/Gender	35 Yrs/Male	Receiving Date	13/04/2024 10:08AM
IP/OP Location	O-OPD	Report Date	13/04/2024 5:36PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9610450468		

BIOCHEMISTRY

CHOLESTEROL TOTAL :- Method: CHOD-PAP enzymatic colorimetric assay.

interpretation:-The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders. HDL CHOLESTEROL :- Method:-Homogenous enzymetic colorimetric method.

Interpretation:-HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease.

LDL CHOLESTEROL :- Method: Homogenous enzymatic colorimetric assay.

Interpretation:-LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived form VLDL rich in TG by the action of various lipolytic enzymes and are Synthesized in the liver. CHOLESTEROL VLDL :- Method: VLDL Calculative

TRIGLYCERIDES :- Method: GPO-PAP enzymatic colorimetric assay.

Interpretation:-High triglycerde levels also occur in various diseases of liver, kidneys and pancreas.

DM, nephrosis, liver obstruction.

CHOLESTEROL/HDL RATIO :- Method: Cholesterol/HDL Ratio Calculative

UREA 21.00 mg/dl 16.60 - 48.50 BUN 10 mg/dl 6 - 20 CREATININE 0.74 mg/dl 0.70 - 1.20 SODIUM 139 mmol/L 136 - 145 POTASSIUM 4.92 mmol/L 3.50 - 5.50 CHLORIDE 98 - 107 106.0 mmol/L URIC ACID 7.1 H mg/dl 3.4 - 7.0 CALCIUM 9.76 mg/dl 8.60 - 10.00

RESULT ENTERED BY : NEETU SHARMA

Albiner Ven

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Sample: Serum

Patient Name UHID	Mr. HARI MOHAN MEENA 40012947	Lab No Collection Date	4030810 13/04/2024 10:00AM
Age/Gender	35 Yrs/Male	Receiving Date	13/04/2024 10:08AM
IP/OP Location	O-OPD	Report Date	13/04/2024 5:36PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9610450468		

BIOCHEMISTRY

CREATININE - SERUM :- Method:-Jaffe method, Interpretation:-To differentiate acute and chronic kidneydisease. URIC ACID :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume. SODIUM: - Method: ISE electrode. Interpretation: -Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the

kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake andkidney reabsorption. POTASSIUM :- Method: ISE electrode. Intrpretation:-Low level: Intake excessive loss formbodydue to diarrhea, vomiting

renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure. CHLORIDE - SERUM :- Method: ISE electrode. Interpretation:-Decrease: reduced dietary intake, prolonged vomiting and reduced renal reabsorption as well as forms of acidosisand alkalosis.

Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate poisoning.

UREA:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerularnephritis and UTI.

CALCIUM TOTAL :- Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usuallyassociated with hypercalcemia. Increased serum calcium levels may also beobserved in multiple myeloma and other neoplastic diseases. Hypocalcemia may

beobserved in hypoparathyroidism, nephrosis, and pancreatitis.

HBA1C

5.4

%

< 5.7% Nondiabetic 5.7-6.4% Pre-diabetic > 6 4% Indicate Diabetes

Known Diabetic Patients

< 7 % Excellent Control

7 - 8 % Good Control > 8 % Poor Control

Method : - Turbidimetric inhibition immunoassay (TINIA)

Interpretation: -Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient. The approximate relationship between HbAlC and mean blood glucose values during the preceding 2 to 3 months.

RESULT ENTERED BY : NEETU SHARMA

AllinayVan

MBBS | MD | INCHARGE PATHOLOGY


Sample: WHOLE BLOOD EDTA

Patient Name	Mr. HARI MOHAN MEENA	Lab No	4030810	
UHID	40012947	Collection Date	13/04/2024 10:00AM	
Age/Gender	35 Yrs/Male	Receiving Date	13/04/2024 10:08AM	
IP/OP Location	O-OPD	Report Date	13/04/2024 5:36PM	
Referred By	Dr. EHS CONSULTANT	Report Status	Final	
Mobile No.	9610450468			

CLINICAL PATHOLOGY

Test Name	Result	Unit	Biological Ref. Range	
URINE SUGAR (POST PRANDIAL)				Sample: Urine
URINE SUGAR (POST PRANDIAL)	NEGATIVE		NEGATIVE	
URINE SUGAR (RANDOM)				Sample: Urine
URINE SUGAR (RANDOM)	NEGATIVE		NEGATIVE	
				Sample: Urine
PHYSICAL EXAMINATION				
VOLUME	20	ml		
COLOUR	PALE YELLOW		P YELLOW	
APPEARANCE	CLEAR		CLEAR	
CHEMICAL EXAMINATION				
РН	6.0		5.5 - 7.0	
SPECIFIC GRAVITY	1.010		1.016-1.022	
PROTEIN	NEGATIVE		NEGATIVE	
SUGAR	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
BLOOD	NEGATIVE			
KETONES	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
UROBILINOGEN	NEGATIVE		NEGATIVE	
LEUCOCYTE	NEGATIVE		NEGATIVE	
MICROSCOPIC EXAMINATION				
WBCS/HPF	1-2	/hpf	0 - 3	
RBCS/HPF	0-0	/hpf	0 - 2	
EPITHELIAL CELLS/HPF	1-2	/hpf	0 - 1	
CASTS	NIL		NIL	
CRYSTALS	NIL		NIL	

RESULT ENTERED BY : NEETU SHARMA



Dr. ABHINAY VERMA

Patient Name	Mr. HARI MOHAN MEENA	Lab No	4030810
UHID	40012947	Collection Date	13/04/2024 10:00AM
Age/Gender	35 Yrs/Male	Receiving Date	13/04/2024 10:08AM
IP/OP Location	O-OPD	Report Date	13/04/2024 5:36PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9610450468		

CLINICAL PATHOLOGY

BACTERIA	NIL	NIL
OHTERS	NIL	NIL

Methodology:-Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific Gravity: Proton re;ease from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue (Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method. interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

RESULT ENTERED BY : NEETU SHARMA

AlbineyVena

Dr. ABHINAY VERMA

Patient Name	Mr. HARI MOHAN MEENA	Lab No	4030810
UHID	40012947	Collection Date	13/04/2024 10:00AM
Age/Gender	35 Yrs/Male	Receiving Date	13/04/2024 10:08AM
IP/OP Location	O-OPD	Report Date	13/04/2024 5:36PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9610450468		

HEMATOLOGY

Test Name	Result	Unit	Biological Ref. Ra	nge
CBC (COMPLETE BLOOD COUNT)				Sample: WHOLE BLOOD EDTA
HAEMOGLOBIN	13.1	g/dl	13.0 - 17.0	
PACKED CELL VOLUME(PCV)	43.3	%	40.0 - 50.0	
MCV	90.6	fl	82 - 92	
МСН	27.4	pg	27 - 32	
MCHC	30.3 L	g/dl	32 - 36	
RBC COUNT	4.78	millions/cu.mm	4.50 - 5.50	
TLC (TOTAL WBC COUNT)	5.98	10^3/ uL	4 - 10	
DIFFERENTIAL LEUCOCYTE COUNT				
NEUTROPHILS	54.6	%	40 - 80	
LYMPHOCYTE	34.8	%	20 - 40	
EOSINOPHILS	2.7	%	1 - 6	
BASOPHIL	0.5 L	%	1 - 2	
MONOCYTES	7.4	%	2 - 10	
PLATELET COUNT	1.98	lakh/cumm	1.500 - 4.500	

HAEMOGLOBIN :- Method:-SLS HemoglobinMethodology by Cell Counter.Interpretation:-Low-Anemia, High-Polycythemia. MCV :- Method:- Calculation bysysmex. MCH :- Method:- Calculation bysysmex. MCHC :- Method:- Calculation bysysmex. MCHC :- Method:- Calculation bysysmex. RBC COUNT :- Method:-Hydrodynamicfocusing.Interpretation:-Low-Anemia,High-Polycythemia.

TLC (TOTAL WEC COUNT) :- Method:-Optical Detectorblock based on Flowcytometry.Interpretation:-High-Leucocytosis, Low-Leucopenia.

NEUTROPHILS :- Method: Optical detectorblock based on Flowcytometry

LYMPHOCYTS :- Method: Optical detectorblock based on Flowcytometry

EOSINOPHILS :- Method: Optical detectorblock based on Flowcytometry MONOCYTES :- Method: Optical detectorblock based on Flowcytometry

BASOPHIL :- Method: Optical detectorblock based on Flowcytometry

PLATELET COUNT :- Method:-Hydrodynamicfocusing method.Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis.

HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia. NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE)

05

mm/1st hr 0 - 15

RESULT ENTERED BY : NEETU SHARMA

AlerinaryVan

Dr. ABHINAY VERMA

Patient Name	Mr. HARI MOHAN MEENA	Lab No	4030810
UHID	40012947	Collection Date	13/04/2024 10:00AM
Age/Gender	35 Yrs/Male	Receiving Date Report Date	13/04/2024 10:08AM
IP/OP Location	O-OPD	Report Status	13/04/2024 5:36PM
Referred By	Dr. EHS CONSULTANT		Final
Mobile No.	9610450468		

Method:-Modified Westergrens. Interpretation:-Increased in infections, sepsis, and malignancy.

End Of Report

RESULT ENTERED BY : NEETU SHARMA

DEPARTMENT OF RADIO DIAGNOSIS

UHID / IP NO	40012947 (11524)	RISNo./Status :	4030810/
Patient Name :	Mr. HARI MOHAN MEENA	Age/Gender :	35 Y/M
Referred By :	Dr. EHS CONSULTANT	Ward/Bed No :	OPD
Bill Date/No :	13/04/2024 9:22AM/ OPSCR24- 25/1235	Scan Date :	
Report Date :	13/04/2024 10:43AM	Company Name:	Mediwheel - Arcofemi Health Care Ltd.

ULTRASOUND STUDY OF WHOLE ABDOMEN

Liver:	Normal in size & echotexture. No obvious significant focal parenchymal mass lesion noted. Intrahepatic biliary radicals are not dilated. Portal vein is normal.
Gall Bladder:	Lumen is clear. Wall thickness is normal. CBD is normal.
Pancreas:	Normal in size & echotexture.
Spleen:	Normal in size & echotexture. No focal lesion seen.
Right Kidney:	Normal in shape, size & location. Echotexture is normal. Corticomedullary differentiation is maintained. No evidence of significant hydronephrosis or obstructive calculus noted.
Left Kidney:	Normal in shape, size & location. Echotexture is normal. Corticomedullary differentiation is maintained. No evidence of significant hydronephrosis or obstructive calculus noted.
Urinary Bladder:	Normal in size, shape & volume. No obvious calculus or mass lesion is seen. Wall thickness is normal.
Prostate:	Is normal in size and echotexture.
Others: <u>IMPRESSION</u> : USG	No significant free fluid is seen in pelvic peritoneal cavity. findings are suggestive of

• No obvious significant sonographic abnormality noted.

Correlate clinically & with other related investigations.

Guren -

DR. SURESH KUMAR SAINI RADIOLOGIST MBBS, MD. Reg. No. 22597, 36208.

DEPARTMENT OF CARDIOLOGY

UHID / IP NO	40012947 (11524)	RISNo./Status :	4030810/
Patient Name : Mr. HARI MOHAN MEENA		Age/Gender :	35 Y/M
Referred By :	Dr. EHS CONSULTANT	Ward/Bed No :	OPD
Bill Date/No :	13/04/2024 9:22AM/ OPSCR24- 25/1235	Scan Date :	
Report Date :	13/04/2024 11:34AM	Company Name:	Final

REFERRAL REASON: HEALTH CHECKUP

2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER

M MODE DIMENSIONS: -

			No	rmal				Normal
IVSD	11.3	6-12mm		LVIDS	30.8	20-40mm		
LVIDD	45.3		32-	57mm		LVPWS	17.7	mm
LVPWD	11.3		6-1	l2mm		AO	29.9	19-37mm
IVSS	17.2		J	nm		LA	30.4	19-40mm
LVEF	60-62		>	55%		RA	-	mm
	DOPPLER	R MEA	SUREN	IENTS &	& CALC	ULATIONS	:	
STRUCTURE	MORPHOLOGY	VELOCITY (m/s)		GRADIENT		REGURGITATION		
				(mml	H <u>g)</u>			
MITRAL	NORMAL	Ε	0.95	e'	-	-		NIL
VALVE		Α	0.60	E/e'	-			
TRICUSPID	NORMAL	E 0.55		-		NIL		
VALVE			A	0	12			
		A 0.43						
AORTIC	NORMAL	1.07		-		NIL		
VALVE								
PULMONARY	NORMAL	0.97				NIL		
VALVE				-				

COMMENTS & CONCLUSION: -

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 60-62%
- NORMAL LV SYSTOLIC FUNCTION
- NORMAL LV DIASTOLIC FUNCTION
- ALL CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

IMPRESSION: - NORMAL BI VENTRICULAR FUNCTIONS

Patient Name UHID	Mr. HARI MOHAN MEENA 348378	Lab No Collection Date	669206 13/04/2024 12:07PM		
Age/Gender	35 Yrs/Male	Receiving Date	13/04/2024 12:11PM		
IP/OP Location	O-OPD	Report Date	13/04/2024 2:27PM		
Referred By	Dr. EHCC Consultant	Report Status	Final		
Mobile No.	9773349797				
BLOOD BANK INVESTIGATION					

Test Name Result Unit **Biological Ref. Range BLOOD GROUPING** "B" Rh Negative

Note :

Both forward and reverse grouping performed.
Test conducted on EDTA whole blood.

End Of Report

RESULT ENTERED BY : Dr. NEHA GUPTA

Neha Cupte

Dr. NEHA GUPTA MBBS | DIHBT | INCHARGE BLOOD CENTRE